We are a clinical stage protein manipulation company creating new therapeutics for patients worldwide. Our platform technologies consist of:
- Protein-protein interaction blockade which prevents specific disease-causing proteins from interacting with each other;
- Protein degradation which harnesses the body's own natural processes to destroy disease causing proteins.
By adopting these approaches, we are expanding the scope of new targets for drug development and unlocking the untapped pool of targets that to date have been considered undruggable. Our goal is to develop a new generation of therapeutics for patients that currently have few options, if any, to treat their diseases effectively.
Company Details
- Employees
- 4
- Founded
- -
- Address
- 2211 Wesbrook Mall, Vancouver,british Columbia V6t 2b5,canada
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://primarypeptides.com
- HQ
- Vancouver, British Columbia
Primary Peptides Questions
Primary Peptides's website is https://primarypeptides.com
Primary Peptides's LinkedIn profile is https://ca.linkedin.com/company/primary-peptides
Primary Peptides has
4 employees.
View email and phone details for 4
employees at Primary Peptides.
Primary Peptides's industry is
Biotechnology Research
Primary Peptides's top competitors are
Reverb Therapeutics,
Pascal Biosciences Inc.,
Nanovation Therapeutics™,
Phoenix Molecular Designs,
Sirona Biochem Corp.,
Xenon Pharmaceuticals Inc.,
Rakovina Therapeutics,
Mydecine Innovations Group,
Me Therapeutics,
Zymeworks Inc..
Primary Peptides's categories are Biotechnology Research
Primary Peptides's founding year is 2013
